Loading clinical trials...
Loading clinical trials...
A Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas
Conditions
Interventions
Ulipristal acetate (UPA)
Placebo
Locations
28
United States
Watson Investigational Site 125
Tucson, Arizona, United States
Watson Investigational Site 102
San Diego, California, United States
Watson Investigational Site 112
Denver, Colorado, United States
Watson Investigational Site 115
Lakewood, Colorado, United States
Watson Investigational Site 116
Milford, Connecticut, United States
Watson Investigational Site 114
Washington D.C., District of Columbia, United States
Start Date
March 31, 2014
Primary Completion Date
March 29, 2016
Completion Date
March 29, 2016
Last Updated
April 30, 2019
NCT00050752
NCT06405997
NCT07474688
NCT01552434
NCT05607602
NCT03304678
Lead Sponsor
Allergan
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions